Mirum Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

• Mirum Pharmaceuticals Inc MIRM.OQ reported a quarterly adjusted loss of 49 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -66 cents. The mean expectation of nine analysts for the quarter was for a loss of 24 cents per share. Wall Street expected results to range from -41 cents to -12 cents per share.

• Revenue rose 42.9% to $99.41 million from a year ago; analysts expected $96.61 million.

• Mirum Pharmaceuticals Inc's reported EPS for the quarter was a loss of 49 cents​.

• The company reported a quarterly loss of $23.79 million.

• Mirum Pharmaceuticals Inc shares had risen by 20.7% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 13.8% in the last three months.​

• In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Mirum Pharmaceuticals Inc is $64.50

This summary was machine generated from LSEG data February 26 at 10:01 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)